%0 Journal Article %A C De Moraes Gomes Lopes %A T Gomes de Almeida %A M Tavares e Silva %A G Pelegrina Neto %A C Martin Gomez %T 406 Epidemiological profile of patients diagnosed with endometrial carcinosarcoma, in a public hospital in the east of são paulo %D 2019 %R 10.1136/ijgc-2019-IGCS.406 %J International Journal of Gynecologic Cancer %P A169-A169 %V 29 %N Suppl 3 %X Objectives To identify the epidemiological profile of patients treated at a public service in the eastern zone of São Paulo with a diagnosis of endometrial carcinosarcoma (CSA).Methods Data collection of patient’s medical records who underwent follow-up at the Oncology Gynecology Santa Marcelina Hospital in Itaquera’s ambulatory from 2001 to 2017, with the diagnosis of CSA. A database analyzing the age, parity, smoking, the main complaint, the use of pre/post-menopausal hormone, the treatment performed, recurrence and death was elaborated.Results In total, 14 patients were attended, aged between 57 and 86 years (mean age 73.4 years) and 80% of cases had vaginal bleeding after menopause. The vast majority were multiparous and had not hormone replacement therapy. They underwent a surgical treatment and 12 cases went through adjuvant therapy with radiotherapy, chemotherapy, brachytherapy, or their associations (85.7% adjuvancy). Six patients developed recurrence (42.8%), with local recurrences (14.2%) and remote recurrences (28.5%), all of them progressing to death within 2 years of follow-up.Conclusions CSAs comprise a tumor‘s group with components of epithelial and mesenchymal origin, predominantly epithelial, and are currently classified as endometrial carcinoma. These represent less than 5% of uterine tumors and exhibit aggressive behavior. As described in the literature, patient’s epidemiological profiles are similar in terms of age, initial symptom of postmenopausal vaginal bleeding and high death rate possibly due to late diagnosis and difficulty to access specialized public services. They differ when compared: parity and use of hormonal therapy. %U https://ijgc.bmj.com/content/ijgc/29/Suppl_3/A169.1.full.pdf